Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that it will present two ophthalmology clinical study results in oral presentations at the Retina China 2026 and the 27th International Retina Forum, to be held in Nanjing from May 21 to 23, 2026.

Oral Presentation 1
Title: A Multicenter, Randomized, Double-Blind, Equivalence Phase 3 Clinical Study Evaluating the Efficacy and Safety of Aflibercept Biosimilar 9MW0813 Versus Reference Product in Patients with Diabetic Macular Edema (DME)
Paper ID: 1409
Presenter: Prof. Wei Wenbin (Beijing Tongren Hospital, Capital Medical University)
Session: Diabetic Retinopathy (I)
Time: May 21, 2026, 16:35–16:40 (local time)

Oral Presentation 2
Title: A Phase II/III Clinical Study Evaluating the Efficacy and Safety of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection 9MW0211 in Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
Paper ID: 1398
Presenter: Prof. Zhang Ming (West China Hospital, Sichuan University)
Session: Fundus Diseases and Systemic Diseases – Macular Disorders (I)
Time: May 22, 2026, 8:25–8:30 (local time)